Search Results

withdrawal of the indication, the NCCN Guidelines for Breast Cancer 13 continue to recommend bevacizumab in combination with paclitaxel in certain circumstances. We also note that the time to regular approval has been progressively decreasing since 2006

Trial of Concurrent Nab-Paclitaxel and Cisplatin With Radiotherapy for Locally Advanced Cervical Cancer • Phase II Trial of Trifluridine/Tipiracil in Combination With Irinotecan in Advanced Biliary Tract Cancers • Real-World Data and Independent

initial testing for all patients. It also includes a number of new recommendations for primary chemotherapy, maintenance treatment, and recurrence treatment. The weekly paclitaxel/carboplatin regimen is a new primary chemotherapy option for all stages

%), and ovarian (7%). Hematologic malignancies constituted 11% of the cohort. Single-agent chemotherapy regimens were most common (233 requests), with docetaxel, paclitaxel, gemcitabine, pemetrexed, and fluorouracil totaling 125 requests. Combination

therapy before locoregional treatment can improve locoregional control, larynx preservation, and overall survival compared with the use of cisplatin and 5-FU alone as an induction regimen. 21 – 23 The regimen of paclitaxel, cisplatin, and 5-FU also

weeks with growth factor support, followed by dose-dense paclitaxel on the same schedule; trastuzumab was initiated with paclitaxel, for a planned 1-year course. She underwent bilateral chest wall irradiation and right-sided regional lymph node

, 22 in which the combination of gemcitabine and nab-paclitaxel also showed improvements in overall survival when compared with single-agent gemcitabine in patients with metastatic PDAC, likewise should prompt further investigation specific to the

-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer . Breast Cancer Res Treat 2012 ; 132 : 747 - 751 . 19 Lesnock JL Farris C Krivak TC . Consolidation paclitaxel is

, were all in early-stage breast cancer. Of these, 9 used a control group of epirubicin and cyclophosphamide followed by a taxane (either paclitaxel or docetaxel). The point of discordance with the NCCN Guidelines was the choice of anthracycline combined

patient was treated with FOLFIRINOX (5-FU/folinic acid/irinotecan/oxaliplatin), but his disease progressed after 6 cycles ( Figure 1A ). He received gemcitabine/nab-paclitaxel as second-line treatment and experienced a partial response. However, he